Literature DB >> 2552657

Herpes simplex virus neurovirulence and productive infection of neural cells is associated with a function which maps between 0.82 and 0.832 map units on the HSV genome.

R L Thompson1, S K Rogers, M A Zerhusen.   

Abstract

A herpes simplex virus (HSV) intertypic recombinant (RE6) has been shown to be completely and specifically non-neurovirulent in mice. Direct intracranial inoculation of 10(8) PFU of RE6 does not result in a lethal encephalitis. Neurovirulent recombinant viruses were generated by cotransfection of RE6 DNA with DNA fragments cloned from the pathogenic HSV-1 strain 17 syn+. It was found that a 1.6-kb fragment mapping between 0.82-0.832 m.u. could restore the neurovirulent phenotype. Recombinants which incorporated at least part of this fragment were at least 100,000-fold more neurovirulent than RE6. The recombinants displayed a greatly enhanced capacity to replicate in mouse brain in vivo, but did not display enhanced replication over that of RE6 in cultured mouse cells at 38.5 degrees. Immunohistochemical analysis of infected mouse brain tissue revealed that the permissive host cell range of the recombinants was dramatically altered from that of RE6. While antigen positive cells were extremely rare in mouse brain tissue infected with RE6, the neurovirulent recombinants produced antigens in many cell types including neurons. Thus, wild-type HSV-1 sequences mapping between 0.82-0.832 m.u. can donate a highly neurovirulent phenotype to RE6.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552657     DOI: 10.1016/0042-6822(89)90186-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  24 in total

1.  Herpes simplex virus type 1 dUTPase mutants are attenuated for neurovirulence, neuroinvasiveness, and reactivation from latency.

Authors:  R B Pyles; N M Sawtell; R L Thompson
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Analysis of herpes simplex virus ICP0 promoter function in sensory neurons during acute infection, establishment of latency, and reactivation in vivo.

Authors:  R L Thompson; May T Shieh; N M Sawtell
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

3.  Comparison of herpes simplex virus reactivation in ganglia in vivo and in explants demonstrates quantitative and qualitative differences.

Authors:  N M Sawtell; R L Thompson
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

4.  Therapeutic implications of new insights into the critical role of VP16 in initiating the earliest stages of HSV reactivation from latency.

Authors:  Richard L Thompson; Nancy M Sawtell
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

5.  Evidence that the herpes simplex virus type 1 ICP0 protein does not initiate reactivation from latency in vivo.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

6.  Comprehensive quantification of herpes simplex virus latency at the single-cell level.

Authors:  N M Sawtell
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

8.  Replication of herpes simplex virus type 1 within trigeminal ganglia is required for high frequency but not high viral genome copy number latency.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

9.  Evidence that the herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system.

Authors:  R B Pyles; R L Thompson
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage.

Authors:  J Chou; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.